<DOC>
	<DOCNO>NCT00812019</DOCNO>
	<brief_summary>The aim present dose range study evaluate safety , tolerability immunogenicity two dos twelve different formulation Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine , adjuvanted MF59 non-adjuvanted , give three week apart follow booster dose 12 month healthy adult 18 40 year age .</brief_summary>
	<brief_title>Dose Ranging Study Evaluate Immunogenicity Safety Adjuvanted Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine Young Adults ( 18-40 Years Old )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Influenza Birds</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Healthy subject age 1840 year , mentally competent , sign informed consent form receive detailed explanation study protocol ; Able understand comply study procedure complete study diary , contact , available study visit . Receipt another investigational agent within 4 week prior enrollment completion safety followup period another study ; unwilling refuse participation another clinical study end study ; Receipt H5N1 vaccine ; Receipt another vaccine within 3 week prior Visit 1 plan vaccination Visit 5 , within 3 week prior Visit 7 Visit 9 ; Influenza vaccination current season within 2 month prior enrollment ( seasonal influenza vaccination allow Visit 5 , later 2 month booster dose ) ; Experience acute disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) within 7 day prior enrollment prior booster dose fever within 3 day prior Visit 1 Visit 7 ; Pregnant breastfeeding , females childbearing potential refuse use acceptable method birth control study period least 6 week follow booster dose ; , sexually active , use reliable birth control method least two month prior study entry ; Any serious disease , : cancer ; autoimmune disease ; diabetes mellitus type I ; diabetes mellitus type II ; diabetes relate genetic defects/syndromes , disease exocrine pancreas infection ; advance arteriosclerotic disease ; moderate severe chronic obstructive pulmonary disease ( COPD ) ; asthma great mild severity and/or exacerbation 2 day per week ; acute progressive hepatic disease ; acute progressive renal disease ; hyperthyroidism ; medically significant bleeding disorder ; history neurological disorder ; Body mass index ( BMI ) â‰¥ 35 kg/m2 BMI obese high muscle mass ; History ( current ) drug alcohol abuse , surgery plan study period condition investigator 's opinion would interfere safety subject evaluation study objective visit schedule ; Hypersensitivity component study vaccine ; Known suspect impairment/alteration immune function ; Members research staff relatives .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>H5N1 Influenza</keyword>
	<keyword>Pandemic Flu</keyword>
	<keyword>MF59 Adjuvant</keyword>
	<keyword>Cell Culture-Derived</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccination</keyword>
	<keyword>H5N1 influenza pandemic</keyword>
</DOC>